Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

SynStitch: A Self-Supervised Learning Network for Ultrasound Image Stitching Using Synthetic Training Pairs and Indirect Supervision
Yao, Xing , Hu, Dewei , Yang, Hao , Lou, Ange , Arenas, Gabriel, Oguz, Baris , Pouch, Alison M. , Schwartz, Nadav , Oğuz, İpek , Yu, Runxuan, Wang, Jiacheng , Lu, Daiwei , Byram, Brett C.

Mayo Clinic

2025 IEEE 22nd International Symposium on Biomedical Imaging (ISBI) | May 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/isbi60581.2025.10981027 | PMID 40539076 Get It

Plasma-CycleGAN: Plasma Biomarker-Guided MRI to Pet Cross-Modality Translation Using Conditional CycleGAN
Chen, Yanxi , Dumitrascu, Celine, Weidman, David, Caselli, Richard J., Reiman, Eric M. , Su, Yi , Chen, Kewei , Caselli, Richard J. , Ashton, Nicholas J. , Wang, Yalin

Mayo Clinic

2025 IEEE 22nd International Symposium on Biomedical Imaging (ISBI) | May 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/isbi60581.2025.10980900 | PMID 40822978 Get It

EViT-UNET: U-Net Like Efficient Vision Transformer for Medical Image Segmentation on Mobile and Edge Devices
Li, Xin , Zhu, Wenhui , Dong, Xuanzhao, Dumitrascu, Oana M. , Dong, Xuanzhao, Wang, Yalin

Mayo Clinic

2025 IEEE 22nd International Symposium on Biomedical Imaging (ISBI) | May 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/isbi60581.2025.10981108 | PMID 40791942 Get It

TPOT: Topology Preserving Optimal Transport in Retinal Fundus Image Enhancement
Dong, Xuanzhao, Zhu, Wenhui , Li, Xin , Sun, Guoxin , Dumitrașcu, Oana , Dong, Xuanzhao, Su, Yi, Wang, Yalin

Mayo Clinic

2025 IEEE 22nd International Symposium on Biomedical Imaging (ISBI) | May 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/isbi60581.2025.10981104 | PMID 40881625 Get It

In vivo human gracilis muscle active force‐length relationship is explained by the sliding filament theory
Wang, Zheng , Persad, Lomas S. , Binder‐Markey, Benjamin I. , Hoffman, E. Matthew , Litchy, William J. , Lieber, Richard L. , Hoffman, Ernest Matthew , Lieber, Richard L , Shin, Alexander Y. , Kaufman, Kenton R.

Mayo Clinic

The Journal of Physiology | May 11, 2025 | Volume: 603 | Issue: 10 | Pages: 3049-3059

10.1113/jp288322 | PMID 40349312 Get It

AbstractThe sliding filament theory explains skeletal muscle fibre force change as a function of length based on the overlap of actin and myosin filaments. Although this length‐tension (LT) relationship has been well investigated in animal models, it is not known whether this microscopic sarcomere LT property can be scaled up five orders of magnitude to explain the LT behaviour of a long human muscle such as the gracilis. The goal of this study is to validate the sarcomere LT curve in humans based on human filament length combined with in vivo experimental data. Intraoperative measurements of maximal tetanic force and muscle‐tendon unit length at four different joint configurations (JC) were obtained from 19 patients undergoing free functioning muscle transfer surgery. With physiologically measured fibre length and estimated sarcomere shortening resulting from tendon compliance, we show that 79.7% variance in isometric force data is explained by a simple human sarcomere LT model. This study demonstrates that the human whole muscle LT relationship can be modelled by the sliding filament theory given patient‐specific fibre length, filament length, tendon compliance and sarcomere shortening. imageKey points Whole human gracilis muscle isometric length‐tension relationships were measured in the operating room. Grouped whole muscle raw length‐tension curves showed no obvious form. The width of each experimental length‐tension curve was highly variable across subjects and used to predict fibre length (serial sarcomere number). After whole muscle length‐tension curves were normalized to each patient's serial sarcomere number, the whole human muscle length‐tension curve was well predicted by the sliding filament theory.
Differences in COVID-19 Vaccination Behaviors Among Adults With Versus Without Chronic Lower Respiratory Diseases: The C4R Study
Lawin, K., Norwood, Arnita F. , Stukovsky, Karen Hinckley , Elkind, Mitchell S, Ortega, Victor E. , Lopez, Victor , Zhang, Ying , Fretts, Amanda M. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Wang, Timothy C. , Lawin, K., Kucharska‐Newton, Anna , Demmer, Ryan T. , Jacobs, David R. , Regan, Elizabeth Anne , Lee, Joyce , Xanthakis, Vanessa , Isasi, Carmen R. , Kanaya, Alka M , Post, Wendy S. , Howard, Virginia J. , Lopez, V., Balte, Pallavi

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7464-A7464

10.1164/ajrccm.2025.211.abstracts.a7464 Get It

Abstract RATIONALE: Chronic lower respiratory diseases (CLRD) confer higher risks from respiratory viral infections, hence CLRD patients are prioritized for influenza, pneumococcal, and COVID-19 vaccination. Nonetheless, vaccine deferral and declination remain common. Given that COVID-19 vaccination is particularly polarizing, and attitudes toward it may differ from other vaccines, we assessed COVID-19 vaccination behaviors and attitudes in adults with versus without CLRD and/or smoking history, which is strongly associated with CLRD risk. METHODS: We pooled data from 10 cohorts participating in the Collaborative Cohort of Cohorts for COVID-19 Research (C4R) that collected pre-pandemic data on self-reported physician diagnosis of asthma or COPD. C4R assessed COVID-19 vaccination status through three waves of standardized questionnaires (2020-2022, 2021-2023, 2023-2024). Prompt COVID-19 vaccination was defined as self-report of receiving at least one COVID-19 vaccine by May 1, 2021. Cumulative COVID-19 vaccine count was self-reported on the Wave 3 Questionnaire. Vaccine attitudes and receipt of influenza and/or pneumococcal vaccines were self-reported on the Wave 1 or 2 Questionnaire. Age-adjusted Poisson regression was used to test associations of vaccination behaviors with CLRD and smoking status at the most recent pre-pandemic exam. RESULTS: Of 20,034 participants (pre-pandemic COPD, 9.3%; asthma, 11.7%; current smoking, 13.4%; former smoking, 36.3%), 64.2% reported prompt COVID-19 vaccination. Among the subset of 10,626 participants completing the Wave 3 Questionnaire in 2023-24, the median COVID-19 vaccine count was 3 (Q1:2, Q3:4). Compared to participants without CLRD, prompt vaccination was more likely in those with asthma (RR=1.04, 95%CI:1.01-1.07, p=0.008) and less likely with COPD (RR=0.94, 95%CI:0.91-0.98, p=0.001), but there were no differences in doses for asthma and COPD. Compared to never smokers, former smoking participants were more likely to receive prompt vaccination (RR=1.11, 95%CI:1.08-1.13, p<0.0001) and more vaccine doses (RR=1.03, 95%CI:1.01-1.05, p=0.015); conversely, current smoking was inversely associated with prompt vaccination (RR=0.94, 95%CI:0.91-0.97, p=0.001) and was associated with fewer doses (RR=0.93, 95%CI:0.89-0.96, p<0.0001). Participants with CLRD versus without CLRD were more likely to report receiving influenza and pneumococcal vaccines, but they were more likely to believe that vaccines are unsafe or ineffective (figure). CONCLUSIONS: COPD was associated with lower likelihood of prompt COVID-19 vaccination. Current smoking was associated with both lower likelihood of prompt COVID-19 vaccination and a lower number of COVID-19 vaccine doses by 2023-24. These associations may be partly attributed to negative vaccine attitudes and beliefs. How the COVID-19 pandemic may have influenced vaccine behaviors and attitudes merits additional study.
Socio-demographic and Clinical Factors Associated With COVID-19 Vaccine Uptake Among Multiethnic US Adults: The C4R Study
Lawin, K., Norwood, Arnita F. , Stukovsky, Karen Hinckley , Elkind, Mitchell S, Ortega, Victor E. , Zhang, Ying , Fretts, Amanda M. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Lawin, K., Wang, Timothy C. , Kucharska‐Newton, Anna , Demmer, Ryan T. , Jacobs, David R. , Regan, Elizabeth Anne , Lee, Joyce , Xanthakis, Vanessa , Isasi, Carmen R. , Kanaya, Alka M , Post, Wendy S. , Howard, Virginia J. , Lopez, V.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7070-A7070

10.1164/ajrccm.2025.211.abstracts.a7070 Get It

Abstract RATIONALE: Deferral and declination of the COVID-19 vaccine is correlated with many factors, including different health guidelines and difficulties accessing the vaccine. In the US, COVID-19 vaccines were made available in tranches of clinical risk starting in December 2020 and were available to all adults on April 19, 2021. In the post-pandemic period, repeating COVID-19 vaccination with updated formulations is broadly recommended. Given that the public health impact of vaccine allocation strategies depends on public acceptance of vaccination, we aimed to evaluate demographic, clinical and social correlates of (1) receiving at least one COVID-19 vaccine by May 1, 2021 (prompt vaccination) and (2) the total number of vaccine doses received (vaccine count) through 2023-2024. METHODS: The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) is a prospective observational meta-cohort study comprising 14 extant NIH-funded population-based cohorts. C4R assessed COVID-19 vaccination using three waves of standardized questionnaires (2020-2021, 2021-2023, 2023-2024). Prompt vaccination was defined by participant self-report of vaccination before May 1, 2021; participants vaccinated after May1, 2021 were classified as non-prompt; participants with missing vaccination information were excluded. Vaccine count was defined by self-report on the 2023-2024 wave Questionnaire. Demographic, clinical and social factors were classified by self-report and/or objective measures from the most recent pre-pandemic cohort exam. Poisson models regressed either prompt vaccination or vaccine count on pre-pandemic factors. RESULTS: Of 17,866 participants (mean age, 6713 years; 60.1% female; 42.1% non-Hispanic White, 22.0% Black, 28.9% Hispanic/Latino, 3.4% American Indian, 2.3% South Asian, 1.4% East Asian), 11,481 (64.3%) reported prompt vaccination. Of the subset of 14,529 participants completing the Wave 3 questionnaire, the median vaccine count in 2023-24 was 3 (Q1, 2; Q3 4). Likelihood of prompt vaccination was higher with greater age, income, and education and with history of diabetes and hypertension; prompt vaccination was less likely with male sex, current smoking, and non-White race and ethnicity (table). Similar associations were observed with respect to vaccine count (table). CONCLUSIONS: In a diverse C4R cohort community-based sample, earlier and greater COVID-19 vaccination was associated with older age and several clinical comorbidities; in contrast, later and lesser vaccine uptake was observed among historically marginalized groups. Whether disparities in COVID-19 vaccination could contribute to disparities in post-COVID-19 conditions merits further investigation.
Associations of SARS-COV-2 Infection and Long COVID With Respiratory Health in the Collaborative Cohort of Cohorts for COVID-19 Research (C4R) Study
Oelsner, Elizabeth C. , Jin, Y., Choi, Yuni , Lawin, K., Elkind, Mitchell S, Gallo, Linda C. , Stukovsky, Karen Hinckley , Newton, A. Kucharska, Norwood, Arnita F. , Ortega, Victor E. , Regan, E.A., Umans, Jason G. , Sun, Yifei , Oelsner, Elizabeth C , Balte, Pallavi , Wang, Timothy C. , Cushman, Mary , Demmer, Ryan T. , Howard, Virginia J. , Isasi, Carmen R. , Jacobs, David R. , Kanaya, Alka M , Lee, Joyce , Newton, Anna‐Kucharska , Gabriel, Kelley Pettee , Post, Wendy S. , Xanthakis, Vanessa

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A6349-A6349

10.1164/ajrccm.2025.211.abstracts.a6349 Get It

Abstract Rationale: SARS-CoV-2 infection may be associated with new or worsening respiratory symptoms that, if persistent, may contribute to “Long COVID.” Research is needed on the prevalence and risk determinants of Long COVID and related respiratory symptoms in adults with and without pre-existing obstructive lung disease or smoking history. Methods: C4R is a prospective, observational study that collected information on SARS-CoV-2 infection using standardized methods across 14 NIH-funded cohorts. The third wave of C4R questionnaires, administered June 2023 to January 2025, assessed self-reported Long COVID via the question, “Do you think that you are experiencing, or have ever experienced, what has been called “long COVID,” or symptoms related to COVID at least a month after your infection?” Questionnaires also assessed the presence (vs absence) of 22 symptoms that have been linked to Long COVID, including cough, shortness of breath, and post-exertional malaise. Pre-pandemic obstructive lung disease (COPD or asthma) and smoking status (ever/never) were harmonized from self-reported data collected at the most recent pre-pandemic cohort exam. Poisson regression was used to assess prevalence ratios (PRs) adjusting for age, sex, BMI, education, and pre-pandemic hypertension, diabetes, cardiovascular disease, and depressive symptoms. PRs for respiratory symptoms were tested according to self-reported Long COVID and history of non-hospitalized or hospitalized infection; effect modification by pre-pandemic lung disease and smoking was assessed by multiplicative interaction terms and in fully stratified models. Results: Among 23,434 questionnaire respondents, 1,484 (6.3%) self-reported Long COVID, including 246/1,262 (19.5%) with pre-pandemic lung disease and 664/4,018 (16.5%) with smoking history. The adjusted PR for Long COVID was 1.17 (95%CI:0.99-1.39;P=0.06) comparing participants with/without lung disease and 1.17 (95%CI:1.04-1.32;P=0.01) comparing participants with/without smoking history. Respiratory symptoms were more prevalent in those with self-reported Long COVID, as well as in those with a history of hospitalized or non-hospitalized infection (Table). Associations were generally stronger in participants without pre-pandemic lung disease (p-interaction<0.05 for all comparisons). Respiratory symptoms were also more prevalent with a history of repeated, and pre-Omicron infections, and were less prevalent among participants vaccinated prior to their first infection; findings were similar even after excluding participants with self-reported Long COVID. Conclusions: Long COVID is common, particularly in adults with pre-existing COPD or asthma or smoking history. Long COVID and history of SARS-CoV-2 infection, including non-hospitalized infections, was associated with greater respiratory symptom burden. Whether SARS-CoV-2 infection or Long COVID are associated with development or progression of obstructive lung diseases warrants future studies.
Increased Exacerbations and Hospitalizations Among PI[asterisk]MZ Compared to PI[asterisk]MM Individuals: An Electronic Health Record Analysis
Wang, Y. , Tremblay, Lauren S Munoz, Azzato, Elizabeth M. , Hutton, R., Wang, Xiaofeng , Ortega, Victor E. , Zein, Joe , Tejwani, Vickram , Baldomero, Arianne K. , Wendt, Chris H. , Attaway, Amy , Bowler, Russell P. , Hatipoğlu, Umur , Strange, Charlie , Stoller, James K.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3249-A3249

10.1164/ajrccm.2025.211.abstracts.a3249 Get It

Abstract RATIONALE The best described endotype of COPD is alpha-1 antitrypsin (AAT) deficiency, which is due to a genetic abnormality in the SERPINA1 gene. Homozygotes for the Z allele (PI[asterisk]ZZ individuals) carry the genotype most commonly associated with severe AAT deficiency, but a highly prevalent endotype is the heterozygous state (PI[asterisk]MZ individuals). Here we test the hypothesis that individuals with PI[asterisk]MZ genotype are at higher risk for COPD exacerbation and healthcare utilization compared to those with no pathogenic variants in the SERPINA1 gene (PI[asterisk]MM individuals). METHODS Real-world data on 4,456 individuals with available AAT genotyping were extracted from the Cleveland Clinic Health System (CCHS) electronic health records (EHR) and analyzed to compare the risk of moderate COPD exacerbation (defined as a short-term steroid prescription), all-cause emergent care (defined as an express care visit, urgent care visit, or emergency department visit), and all-cause hospitalization between individuals with PI[asterisk]MZ vs. PI[asterisk]MM genotypes. Cox proportional hazards models were used to adjust for age, sex, race, BMI, smoking status, comorbidity count, liver disease diagnosis, and median income by zip code.To assess the effect of AAT levels on outcomes, we categorized participants into three groups based on AAT level and used 90 mg/dL as a threshold given it is the lower limit of the normal reference range and genotype: MM individuals with an AAT level >90 mg/dL, MZ >90 mg/dL and MZ <90 mg/dL. To assess the effect of PI[asterisk]MZ genotype among individuals with pre-existing lung disease, we performed a subgroup analysis of individuals with at least a six-month inhaler prescription. RESULTS In this cohort, 308 individuals had a PI[asterisk]MZ genotype. PI[asterisk]MZ was associated with increased risk for moderate COPD exacerbations (adjusted HR [95% CI]: 1.66 [1.27, 2.17]) and hospitalizations (adjusted HR [95% CI]: 1.44 [1.19, 1.75]) compared to PI[asterisk]MM. The risk of hospitalization was higher among PI[asterisk]MZ individuals with AAT levels <90 mg/dL (adjusted HR [95% CI]: 1.59 [1.14, 2.23]) but not in those with AAT levels >90 mg/dL, as compared to PI[asterisk]MM. Sensitivity analysis in those treated with inhaler therapy showed overall similar results. CONCLUSIONS Increased hospitalizations and moderate COPD exacerbations among PI[asterisk]MZ individuals compared to PI[asterisk]MM individuals merit future prospective studies to better characterize the longitudinal course and healthcare utilization among those with an PI[asterisk]MZ genotype. Given the high prevalence of these carriers globally, PI[asterisk]MZ represents a COPD phenotype that invites additional investigation to identify biomarkers of worse disease and treatable traits.
Healthcare Resource Utilization Associated With Treatment for Refractory Mycobacterium Avium Complex Lung Disease: Comparison of Amikacin Liposome Inhalation Suspension (ALIS) vs Non-ALIS Antibiotic Treatment
Aksamit, Timothy R. , Waweru, Catherine, WELCH, EMILY , Markson, Leona E., Wang, Ping

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3172-A3172

10.1164/ajrccm.2025.211.abstracts.a3172 Get It

Abstract Rationale Amikacin liposome inhalation suspension (ALIS), as part of a combination antibacterial regimen, is currently the only FDA-approved treatment for patients with refractory Mycobacterium avium complex lung disease (rMACLD). MAC is the most common cause of nontuberculous mycobacterial lung disease (NTMLD). A real-world evidence study demonstrated significant decreases in hospitalizations from baseline over a 12-month follow-up period following ALIS initiation; however, study conclusions were limited by the absence of a comparator arm. In this study, we compared healthcare resource utilization in US patients who initiated ALIS versus non-ALIS antibiotic treatment for possible rMACLD. Methods This was a retrospective claims analysis using the Merative™ MarketScan® databases between 2016 and 2021. As no diagnosis codes for MACLD exist in claims, we defined 2 cohorts of patients receiving treatment for possible rMACLD as follows: 1) patients who initiated ≥28 days of continuous treatment with ALIS; and 2) patients who initiated ≥28 days of continuous treatment with ≥1 non-ALIS antibiotic used to treat rMACLD (i.e., parenteral aminoglycoside, clofazimine, fluoroquinolones, linezolid, tedizolid, or bedaquiline) ≥6 months after initiating treatment used for MACLD (i.e., with a combination of ≥2 antibiotics from a macrolide, ethambutol, and a rifamycin). The date of initiating treatment with ALIS or non-ALIS antibiotic for rMACLD was referred to as the index date. Other inclusion criteria: ≥1 diagnosis code for NTMLD anytime pre-index, ≥6 months continuous eligibility pre-index, and ≥12 months continuous eligibility post-index. Hospitalizations (all-cause, respiratory-related, NTMLD-related) and emergency room (ER) visits at 0-6 and 7-12 month post-index periods were compared with baseline (6 month pre-index period) per treatment arm. Results A total of 116 patients comprised the ALIS cohort and 63 patients the non-ALIS cohort. In the ALIS cohort, statistically significant reductions from baseline in all-cause, respiratory-related, and NTMLD-related hospitalizations were observed during the 7-12 month post-index period (Table). In contrast, the non-ALIS cohort did not show significant reductions from baseline in hospitalizations at follow-up. No statistically significant changes from baseline in ER visits were observed in either group. Conclusions Patients treated with ALIS for rMACLD had statistically significant reductions in hospitalizations from baseline during the 7-12 month post-index period, whereas no statistically significant improvements in hospitalizations were observed in the non-ALIS antibiotics group.